<DOC>
	<DOCNO>NCT01505491</DOCNO>
	<brief_summary>This trial investigate pharmacokinetics , safety tolerability BI 695501 establish pharmacokinetic equivalence BI 695501 adalimumab .</brief_summary>
	<brief_title>Pharmacokinetics Safety Study BI 695501 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy male 2 . Body mass index ( BMI ) =18.5 =29.9 kg/m2 Exclusion criterion : 1 . Any clinically relevant abnormal find medical examination ( include blood pressure , pulse rate electrocardiogram ) deviate normal clinical relevance 2 . Any evidence clinically relevant previous concomitant disease judge investigator . 3 . Chronic relevant acute infection . A negative result Human Immunodeficiency Virus , Hepatitis B Hepatitis C test require participation . 4 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) 5 . Intake prescribed overthecounter drug long halflife ( &gt; 24 hour ) within least one month le 5 halflives respective drug prior administration trial 6 . Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) 7 . Inability refrain smoking day confinement study center 8 . Alcohol abuse ( average 30 g/day ) 9 . Current drug abuse</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>